Blog
RSS FeedPosted by Michael Wonder on 21 Jul 2022
ATAGI update following weekly COVID-19 meeting (20 July 2022)
21 July 2022 - The ATAGI met on 20 July 2022 to consider the latest developments relating to COVID-19 immunisation. ...
Posted by Michael Wonder on 20 Jul 2022
Statement by President Joe Biden on FDA and CDC authorising Novavax’s COVID-19 vaccine for adults
19 July 2022 - Today is another step forward in our nation’s fight against the virus. Following an independent scientific review ...
Posted by Michael Wonder on 20 Jul 2022
Pfizer and BioNTech complete submission to European Medicines Agency for Omicron BA.1 adapted bivalent vaccine candidate
19 July 2022 - Pfizer and BioNTech today announced they have completed a submission to the EMA for an Omicron-adapted bivalent ...
Posted by Michael Wonder on 19 Jul 2022
ATAGI update following weekly COVID-19 meeting (13 July 2022)
19 July 2022 - On Wednesday 13 July 2022, ATAGI met to consider the latest developments relating to COVID-19 immunisation. ...
Posted by Michael Wonder on 19 Jul 2022
EU regulator reviews Pfizer-BioNTech COVID shot in children as young as 6 months
18 July 2022 - The European Medicines Agency on Monday started reviewing a low-dose version of BioNTech and Pfizer’s COVID-19 ...
Posted by Michael Wonder on 19 Jul 2022
TGA provisionally approves Moderna COVID-19 vaccine (Spikevax) for use in children from 6 months
19 July 2022 - The TGA has provisionally approved a paediatric dose of the Moderna COVID-19 vaccine, Spikevax, for use ...
Posted by Michael Wonder on 18 Jul 2022
Aussies could get omicron targeted jab earlier than most
18 July 2022 - Australia could become one of the first countries in the world to administer an omicron-specific vaccine, ...
Posted by Michael Wonder on 15 Jul 2022
Health Canada authorises use of Moderna COVID-19 vaccine in children 6 months to 5 years of age
14 July 2022 - Today, Health Canada authorised the use of the Moderna Spikevax COVID-19 vaccine in children 6 months to ...
Posted by Michael Wonder on 14 Jul 2022
COVID-19 vaccine safety report (14 July 2022)
14 July 2022 - To 10 July 2022, the TGA has received 609 reports which have been assessed as likely to ...
Posted by Michael Wonder on 13 Jul 2022
FDA authorises emergency use of Novavax COVID-19 vaccine, adjuvanted
13 July 2022 - Today, the U.S. FDA issued an emergency use authorisation for the Novavax COVID-19 vaccine, adjuvanted for the ...
Posted by Michael Wonder on 11 Jul 2022
ECDC and EMA update recommendations on additional booster doses of mRNA COVID-19 vaccines
11 July 2022 - The European Centre for Disease Prevention and Control and the EMA are recommending that second booster ...
Posted by Michael Wonder on 10 Jul 2022
Novavax files in Switzerland for expanded conditional marketing authorisation of Nuvaxovid COVID-19 vaccine for adolescents aged 12 through 17 and as a booster in individuals aged 18 and over
7 July 2022 - Novavax today announced the submission of a request to Swissmedic to expand the conditional marketing authorisation ...
Posted by Michael Wonder on 10 Jul 2022
Novavax Nuvaxovid COVID-19 vaccine conditionally authorised in the European Union for adolescents aged 12 through 17
5 July 2022 - Nuvaxovid COVID-19 vaccine is the first protein-based option for adolescents aged 12 through 17 in Europe. ...
Posted by Michael Wonder on 10 Jul 2022
Monkeypox: a preventive vaccination offered to those most at risk of exposure
8 July 2022 - Faced with the spread of the Monkeypox virus, the kinetics of the epidemic and the difficulties of ...
Posted by Michael Wonder on 10 Jul 2022
Pfizer and BioNTech submit a variation to EMA for the vaccination of children 6 months to less than 5 years with Comirnaty
8 July 2022 - y 8, 2022 — Pfizer and BioNTech today announced that the companies have submitted a variation to ...